Somewhat Positive Media Coverage Somewhat Unlikely to Impact Versartis (VSAR) Stock Price

News headlines about Versartis (NASDAQ:VSAR) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Versartis earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.065913640775 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Versartis (VSAR) traded down $0.23 during trading hours on Tuesday, hitting $2.05. 1,199,700 shares of the company’s stock traded hands, compared to its average volume of 824,240. The firm has a market capitalization of $73.41, a P/E ratio of -0.52 and a beta of 2.35. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.11. Versartis has a fifty-two week low of $1.60 and a fifty-two week high of $24.00.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.78). During the same period last year, the business posted ($0.92) EPS. research analysts expect that Versartis will post -4.14 earnings per share for the current fiscal year.

Several analysts recently weighed in on VSAR shares. ValuEngine downgraded shares of Versartis from a “sell” rating to a “strong sell” rating in a report on Friday, September 22nd. SunTrust Banks downgraded shares of Versartis from a “buy” rating to a “hold” rating and dropped their target price for the company from $25.00 to $4.00 in a report on Friday, September 22nd. Canaccord Genuity reiterated a “buy” rating and issued a $9.00 target price (down previously from $28.00) on shares of Versartis in a report on Friday, September 22nd. Barclays downgraded shares of Versartis from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $28.00 to $4.00 in a research note on Friday, September 22nd. Finally, Cowen downgraded shares of Versartis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $45.00 to $3.00 in a research note on Friday, September 22nd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $5.63.

In other Versartis news, Director Srinivas Akkaraju purchased 513,872 shares of the company’s stock in a transaction on Monday, December 4th. The stock was acquired at an average price of $2.21 per share, for a total transaction of $1,135,657.12. Following the completion of the purchase, the director now directly owns 14,955 shares in the company, valued at approximately $33,050.55. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders sold 2,769 shares of company stock valued at $7,061. Insiders own 10.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/09/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-versartis-vsar-stock-price.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit